Astec LifeSciences Limited's (NSE:ASTEC) Profit Outlook
We feel now is a pretty good time to analyse Astec LifeSciences Limited's (NSE:ASTEC) business as it appears the company may be on the cusp of a considerable accomplishment. Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The ₹13b market-cap company’s loss lessened since it announced a ₹809m loss in the full financial year, compared to the latest trailing-twelve-month loss of ₹796m, as it approaches breakeven. Many investors are wondering about the rate at which Astec LifeSciences will turn a profit, with the big question being “when will the company breakeven?” In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.
Consensus from 2 of the Indian Chemicals analysts is that Astec LifeSciences is on the verge of breakeven. They anticipate the company to incur a final loss in 2027, before generating positive profits of ₹246m in 2028. Therefore, the company is expected to breakeven roughly 2 years from now. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 115% year-on-year, on average, which is rather optimistic! Should the business grow at a slower rate, it will become profitable at a later date than expected.
Given this is a high-level overview, we won’t go into details of Astec LifeSciences' upcoming projects, however, keep in mind that generally a high growth rate is not out of the ordinary, particularly when a company is in a period of investment.
View our latest analysis for Astec LifeSciences
Before we wrap up, there’s one issue worth mentioning. Astec LifeSciences currently has a relatively high level of debt. Generally, the rule of thumb is debt shouldn’t exceed 40% of your equity, which in Astec LifeSciences' case is 99%. A higher level of debt requires more stringent capital management which increases the risk in investing in the loss-making company.
Next Steps:
There are key fundamentals of Astec LifeSciences which are not covered in this article, but we must stress again that this is merely a basic overview. For a more comprehensive look at Astec LifeSciences, take a look at Astec LifeSciences' company page on Simply Wall St. We've also put together a list of essential factors you should look at:
- Valuation: What is Astec LifeSciences worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether Astec LifeSciences is currently mispriced by the market.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Astec LifeSciences’s board and the CEO’s background.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.